Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer with and Without Pembrolizumab

Next Previous
Search
Trial Profile

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer with and Without Pembrolizumab

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LNS 8801 (Primary) ; Pembrolizumab (Primary)
  • Indications Colorectal cancer; Gastric cancer; Haematological malignancies; Lymphoma; Malignant melanoma; Mesothelioma; Nasopharyngeal cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Pancreatic cancer; Skin cancer; Solid tumours; Uterine cancer; Uveal melanoma
  • Focus Adverse reactions; Biomarker; First in man; Therapeutic Use
  • Sponsors Linnaeus Therapeutics

    • Most Recent Events

    • 13 Dec 2024 Planned End Date changed from 15 Dec 2024 to 15 Dec 2027.
    • 13 Dec 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Dec 2026.
    • 16 Sep 2024 According to a Linnaeus Therapeutics media release, clinical data from its dose-expansion cohort of LNS8801 as a monotherapy in patients with metastatic cutaneous melanoma who could not tolerate immunotherapy due to prior immune-related adverse events of this study presented at the 2024 ESMO Annual Meeting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top